Presence of late gadolinium enhancement in Duchenne muscular dystrophy patients is associated with age and global ventricular function 
Background
The Duchenne muscular dystrophy (DMD) associated cardiac disease results in significant morbidity and mortality usually resulting in death by the second to third decade of life. End-stage cardiac pathology consists of alternating areas of myocyte hypertrophy, atrophy and fibrosis manifesting as late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) evaluation. There has been considerable interest in detecting the presence of LGE, and previous studies have associated LGE with global ventricular dysfunction as assessed by ejection fraction (EF). However, given the genetic origins and underlying pathogenesis of DMDassociated cardiac disease, we hypothesized that LGE is prevalent in patients without overt disease. using SAS (version 9.2; SAS Institute Inc, Cary, NC) and reported as percentages and odds ratios (OR) with confidence interval (CI).
Methods

Results
We analyzed 247 CMR studies in individual DMD patients and compared the presence of LGE to age and EF ( Figure 1A-C) . The presence of LGE was strongly associated with EF; LGE was present in 85% of patients with EF < 55% whereas only 15% of those with normal EF were LGE positive (OR = 18.8, CI 6.2-57.1).
LGE presence was also strongly associated with age; LGE was present in only 13% of those < 10 years (OR = 1), in 26% of those 10-15 years (OR = 3.4, CI 1.8 -6.7) and in 55% >15 years of age (OR = 8.0, CI 3.4 -18.6) ( Table 1) .
Conclusions
This large series shows a high prevalence of LGE in DMD patients. LGE is strongly associated with age and global dysfunction. Thus it is most common in older patients with reduced EF. However, it is also detected in young DMD patients with normal EF. LGE may be a useful biomarker for detection of progression of DMDassociated cardiac disease. As such, it may have important implications to clinical care and research. 
